Mirum Pharmaceuticals Inc. said on Sept. 29 the company’s drug became the first U.S. approved therapy for treating itching in patients with a rare liver disorder called Alagille syndrome (ALGS).
https://www.pharmalive.com/wp-content/uploads/2021/06/U.S.-FDA-declines-to-approve-Avenues-non-opioid-painkiller-again-shares-drop-Reuters-6-14-21.jpg503960Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-09-29 18:22:372021-09-30 01:11:35Mirum’s oral drug becomes first U.S. approved Alagille syndrome therapy